The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination

Vaccine

Volumn 29, Issue 33, 2011, Pages 5393-5398

  Himes, Roy ^b   Lee, Sora ^a   McMenigall, Kim ^a   Russell Jones, Greg ^a  

^a Apollo Life Sciences   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Adjuvant; Cutaneous; Immunity; Micro emulsion; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MURABUTIDE; PHOSPHORYL LIPID A; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FOOT EDEMA; HUMORAL IMMUNITY; IMMUNIZATION; INFLAMMATION; INNATE IMMUNITY; MICROEMULSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ABSORPTION; TETANUS; TISSUE INJURY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C57BL; SKIN; TETANUS TOXOID; VACCINATION;

EID: 79960370598     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.085     Document Type: Article

References (31)

1. Stoitzner P., Holzmann S., McLellan A.D., Ivarsson L., Stossel H., Kapp M., et al. Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207. J Invest Dermatol 2003, 120(February (2)):266-274.
2. Jackson L.A., Austin G., Chen R.T., Stout R., DeStefano F., Gorse G.J., et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001, 19(September (32)):4703-4709.
3. Williams J., Fox-Leyva L., Christensen C., Fisher D., Schlicting E., Snowball M., et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000, 18(March (18)):1939-1943.
4. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5(December (12)):905-916.
5. Katou F., Ohtani H., Saaristo A., Nagura H., Motegi K. Immunological activation of dermal Langerhans cells in contact with lymphocytes in a model of human inflamed skin. Am J Pathol 2000, 156(February (2)):519-527.
6. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March (6673)):245-252.
7. Wang B., Amerio P., Sauder D.N. Role of cytokines in epidermal Langerhans cell migration. J Leukoc Biol 1999, 66(July (1)):33-39.
8. Himes R., Lee S., McMenigall K., Russell-Jones G.J. Reduction in inflammation in the footpad of carrageenan treated mice following the topical administration of anti-TNF molecules formulated in a micro-emulsion. J Control Release 2010, 145(3):210-213.
9. Albanesi C., Scarponi C., Giustizieri M.L., Girolomoni G. Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 2005, 4(June (3)):329-334.
10. Hendriksen C.F., Slob W., vd Gun J.W., Westendorp J.H., den Bieman M., Hesp A., et al. Immunogenicity testing of diphtheria and tetanus vaccines by using isogenic mice with possible implications for potency testing. Lab Anim 1994, 28(April (2)):121-129.
11. Gupta R.K., Siber G.R. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals 1994, 22(March (1)):53-63.
12. Clements C.J., Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002, 20(May (Suppl. 3)):S24-33.
13. Chedid L.A., Parant M.A., Audibert F.M., Riveau G.J., Parant F.J., Lederer E., et al. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 1982, 35(February (2)):417-424.
14. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316(June (5831)):1628-1632.
15. Gray D.F., Jennings P.A. Allergy in experimental mouse tuberculosis. Am Rev Tuberc 1955, 72(August (2)):171-195.
16. Lefebvre H.P., Laroute V., Braun J.P., Lassourd V., Toutain P.L. Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release. Vet Res 1996, 27(4-5):343-361.
17. Robert C., Kupper T.S. Inflammatory skin diseases T cells, and immune surveillance. N Engl J Med 1999, 341(December (24)):1817-1828.
18. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996, 2(October (10)):1122-1128.
19. Tuting T., DeLeo A.B., Lotze M.T., Storkus W.J. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997, 27(October (10)):2702-2707.
20. Barry M.A., Johnston S.A. Biological features of genetic immunization. Vaccine 1997, 15(June (8)):788-791.
21. Shi Y., Rock K.L. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur J Immunol 2002, 32(January (1)):155-162.
22. von Stebut E., Udey M.C. Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 2004, 6(October (12)):1102-1109.
23. Evans T.G., Smith D., Pearson R.D. Humoral factors and nonspecific immune suppression in Syrian hamsters infected with Leishmania donovani. J Parasitol 1990, 76(April (2)):212-217.
24. Akuffo H.O., Fehniger T.E., Britton S. Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. J Immunol 1988, 141(October (7)):2461-2466.
25. Flacher V., Douillard P., Ait-Yahia S., Stoitzner P., Clair-Moninot V., Romani N., et al. Expression of langerin/CD207 reveals dendritic cell heterogeneity between inbred mouse strains. Immunology 2008, 123(March (3)):339-347.
26. Sumaria N., Roediger B., Ng L.G., Qin J., Pinto R., Cavanagh L.L., et al. Cutaneous immunosurveillance by self-renewing dermal gammadelta T cells. J Exp Med 2011, 208(March (3)):505-518.
27. Bergstresser P.R., Fletcher C.R., Streilein J.W. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dermatol 1980, 74(February (2)):77-80.
28. O'Connell P.J., Li W., Wang Z., Specht S.M., Logar A.J., Thomson A.W. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol 2002, 168(January (1)):143-154.
29. Gudjonsson J.E., Elder J.T., Psoriasis: epidemiology Clin Dermatol 2007, 25(November-December (6)):535-546.
30. Curry J.L., Qin J.Z., Bonish B., Carrick R., Bacon P., Panella J., et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003, 127(February (2)):178-186.
31. Picker L.J., Treer J.R., Ferguson-Darnell B., Collins P.A., Bergstresser P.R., Terstappen L.W. Control of lymphocyte recirculation in man II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol 1993, 150(February (3)):1122-1136.